Medical expert video library
NCCN GUIDELINES®
Experts discuss the National Comprehensive Cancer Network® (NCCN®) Category 1 Preferred 1L treatment options
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
Dr Cohen has been compensated for his time by Novartis Pharmaceuticals Corporation.
1L, first line; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor.
START & STAY
Expert perspective on dosing and patient adherence in HR+/HER2- mBC
Dr Nick McAndrew shares his perspective on simple dose reductions with KISQALI + AI or fulvestrant and how to improve adherence in patients with HR+/HER2- mBC.
Dr McAndrew has been compensated for his time by Novartis Pharmaceuticals Corporation.
HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; mBC, metastatic breast cancer.
ROUND TABLE
Round table discussion: Managing QT interval and ECG assessments
Drs Dent, Guha, and Moore discuss a hypothetical premenopausal patient with HR+/HER2- mBC. The team discusses managing QT interval and ECG assessments when starting the patients on KISQALI in combination with AI or fulvestrant, as well as managing them throughout treatment.
Drs Dent, Guha, and Moore have been compensated for their time by Novartis Pharmaceuticals Corporation.
Round table discussion: Addressing DDIs
Drs Dent, Guha, and Moore discuss a hypothetical postmenopausal patient with HR+/HER2- mBC. The team addresses potential drug-drug interactions with medications the patient is currently taking to manage other conditions.
Drs Dent, Guha, and Moore have been compensated for their time by Novartis Pharmaceuticals Corporation.
Round table discussion: Addressing cardiac comorbidities
Drs Dent, Guha, and Moore discuss a hypothetical postmenopausal patient with HR+/HER2- mBC with preexisting cardiac conditions, how these may factor into her treatments, and the best method for starting treatment with KISQALI in combination with AI or fulvestrant.
Drs Dent, Guha, and Moore have been compensated for their time by Novartis Pharmaceuticals Corporation.
DDI, drug-drug interaction; ECG, electrocardiogram.